FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4243603879> ?p ?o ?g. }

• W4243603879 abstract "Background Age‐related macular degeneration (AMD) is a progressive late onset disorder of the macula affecting central vision. Age‐related macular degeneration is the leading cause of blindness in people over 65 years in industrialized countries. Recent epidemiologic, genetic, and pathological evidence has shown AMD shares a number of risk factors with atherosclerosis, leading to the hypothesis that statins may exert protective effects in AMD. Objectives The objective of this review was to examine the effectiveness of statins compared with other treatments, no treatment, or placebo in delaying the onset and progression of AMD. Search methods We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 6), Ovid MEDLINE, Ovid MEDLINE In‐Process and Other Non‐Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to June 2014), EMBASE (January 1980 to June 2014), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to June 2014), PubMed (January 1946 to June 2014), the metaRegister of Controlled Trials (mRCT) (www.controlled‐trials.com), ClinicalTrials.gov (www.clinicaltrials.gov), and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 5 June 2014. Selection criteria We included randomized controlled trials (RCTs) that compared statins with other treatments, no treatment, or placebo in participants who were either susceptible to or diagnosed as having early stages of AMD. Data collection and analysis We used standard methodological procedures expected by The Cochrane Collaboration. Two authors independently evaluated the search results against the selection criteria, abstracted data, and assessed risk of bias. We did not perform meta‐analysis due to heterogeneity in the interventions and outcomes among the included studies. Main results Two RCTs with 144 total participants met the selection criteria. Both trials compared simvastatin versus placebo in older people (> 50 or 60 years) with high risk of developing AMD (drusen present on examination). The larger trial with 114 participants was conducted in Australia and used a higher dose (40 mg daily) of simvastatin for three years. Participants and study personnel in this trial were adequately masked; however, data were missing for 30% of participants at three years follow‐up. The smaller trial of 30 participants was conducted in Italy and used a lower dose (20 mg) of simvastatin for three months. This trial reported insufficient details to assess the risk of bias. Neither trial reported data for change in visual acuity. Analysis of 30 participants in the smaller trial did not show a statistically significant difference between the simvastatin and placebo groups in visual acuity values at three months of treatment (decimal visual acuity 0.21 ± 0.56 in simvastatin group and 0.19 ± 0.40 in placebo group) or 45 days after the completion of treatment (decimal visual acuity 0.20 ± 0.50 in simvastatin group and 0.19 ± 0.48 in placebo group). The lack of a difference in visual acuity was not explained by lens or retina status, which remained unchanged during and after the treatment period for both groups. Preliminary analyses of 42 participants who had completed 12 months follow‐up in the larger trial did not show a statistically significant difference between simvastatin and the placebo groups for visual acuity, drusen score, or visual function (effect estimates and confidence intervals were not available). Complete data for these outcomes at three years follow‐up were not reported. At three years, the effect of simvastatin in slowing progression of AMD compared with placebo was uncertain (odds ratio 0.51, 95% confidence interval 0.23 to 1.09). One trial did not report adverse outcomes. The second trial reported no difference between groups in terms of adverse events such as death, muscle aches, and acute hepatitis. Authors' conclusions Evidence from currently available RCTs is insufficient to conclude that statins have a role in preventing or delaying the onset or progression of AMD." @default.
• W4243603879 created "2022-05-12" @default.
• W4243603879 creator A5046018060 @default.
• W4243603879 creator A5051080702 @default.
• W4243603879 creator A5072760500 @default.
• W4243603879 date "2015-02-11" @default.
• W4243603879 modified "2023-09-27" @default.
• W4243603879 title "Statins for age-related macular degeneration" @default.
• W4243603879 cites W1543801259 @default.
• W4243603879 cites W1558479151 @default.
• W4243603879 cites W1580351516 @default.
• W4243603879 cites W180812339 @default.
• W4243603879 cites W1882214116 @default.
• W4243603879 cites W1922994408 @default.
• W4243603879 cites W1941607167 @default.
• W4243603879 cites W1963621262 @default.
• W4243603879 cites W1970371629 @default.
• W4243603879 cites W1973459017 @default.
• W4243603879 cites W1975032911 @default.
• W4243603879 cites W1985423172 @default.
• W4243603879 cites W1988191877 @default.
• W4243603879 cites W1992859141 @default.
• W4243603879 cites W1994945285 @default.
• W4243603879 cites W1999131068 @default.
• W4243603879 cites W2041745079 @default.
• W4243603879 cites W2043663390 @default.
• W4243603879 cites W2047671141 @default.
• W4243603879 cites W2049462104 @default.
• W4243603879 cites W2053854676 @default.
• W4243603879 cites W2066326071 @default.
• W4243603879 cites W2073741050 @default.
• W4243603879 cites W2074303040 @default.
• W4243603879 cites W2092816889 @default.
• W4243603879 cites W2114209995 @default.
• W4243603879 cites W2134048257 @default.
• W4243603879 cites W2140181275 @default.
• W4243603879 cites W2144469043 @default.
• W4243603879 cites W2148959041 @default.
• W4243603879 cites W2151289732 @default.
• W4243603879 cites W2154992699 @default.
• W4243603879 cites W2156434735 @default.
• W4243603879 cites W2167734104 @default.
• W4243603879 cites W2169968952 @default.
• W4243603879 cites W2172216858 @default.
• W4243603879 cites W2464204207 @default.
• W4243603879 cites W2598520882 @default.
• W4243603879 cites W4210963746 @default.
• W4243603879 cites W4230108892 @default.
• W4243603879 cites W4238940178 @default.
• W4243603879 cites W4239845442 @default.
• W4243603879 cites W4244908295 @default.
• W4243603879 cites W4246295494 @default.
• W4243603879 cites W4253904110 @default.
• W4243603879 cites W4255667921 @default.
• W4243603879 cites W4297900156 @default.
• W4243603879 cites W4298128547 @default.
• W4243603879 cites W4301327167 @default.
• W4243603879 doi "https://doi.org/10.1002/14651858.cd006927.pub4" @default.
• W4243603879 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25675254" @default.
• W4243603879 hasPublicationYear "2015" @default.
• W4243603879 type Work @default.
• W4243603879 citedByCount "11" @default.
• W4243603879 countsByYear W42436038792016 @default.
• W4243603879 countsByYear W42436038792018 @default.
• W4243603879 countsByYear W42436038792020 @default.
• W4243603879 countsByYear W42436038792023 @default.
• W4243603879 crossrefType "reference-entry" @default.
• W4243603879 hasAuthorship W4243603879A5046018060 @default.
• W4243603879 hasAuthorship W4243603879A5051080702 @default.
• W4243603879 hasAuthorship W4243603879A5072760500 @default.
• W4243603879 hasBestOaLocation W42436038792 @default.
• W4243603879 hasConcept C118487528 @default.
• W4243603879 hasConcept C126322002 @default.
• W4243603879 hasConcept C142724271 @default.
• W4243603879 hasConcept C168563851 @default.
• W4243603879 hasConcept C17744445 @default.
• W4243603879 hasConcept C187212893 @default.
• W4243603879 hasConcept C199539241 @default.
• W4243603879 hasConcept C204787440 @default.
• W4243603879 hasConcept C27081682 @default.
• W4243603879 hasConcept C2776403814 @default.
• W4243603879 hasConcept C2779473830 @default.
• W4243603879 hasConcept C44249647 @default.
• W4243603879 hasConcept C535046627 @default.
• W4243603879 hasConcept C71924100 @default.
• W4243603879 hasConcept C82789193 @default.
• W4243603879 hasConcept C95190672 @default.
• W4243603879 hasConceptScore W4243603879C118487528 @default.
• W4243603879 hasConceptScore W4243603879C126322002 @default.
• W4243603879 hasConceptScore W4243603879C142724271 @default.
• W4243603879 hasConceptScore W4243603879C168563851 @default.
• W4243603879 hasConceptScore W4243603879C17744445 @default.
• W4243603879 hasConceptScore W4243603879C187212893 @default.
• W4243603879 hasConceptScore W4243603879C199539241 @default.
• W4243603879 hasConceptScore W4243603879C204787440 @default.
• W4243603879 hasConceptScore W4243603879C27081682 @default.
• W4243603879 hasConceptScore W4243603879C2776403814 @default.
• W4243603879 hasConceptScore W4243603879C2779473830 @default.
• W4243603879 hasConceptScore W4243603879C44249647 @default.
• W4243603879 hasConceptScore W4243603879C535046627 @default.

• next